东诚药业：控股子公司获放射性药品生产许可证

Core Viewpoint - Dongcheng Pharmaceutical (002675) announced that its subsidiary, Lanacheng, has received a production license for radioactive drugs from the Shandong Provincial Drug Administration, which is expected to have no significant impact on the company's current performance [1] Group 1 - Lanacheng has obtained the production license for radioactive drugs, allowing it to proceed with commercial production once it receives the marketing approval for Fluorine-18 labeled somatostatin analog injection [1]